SP140L (Gene)

Synonyms:ENTREZ:93349, HGNC:25105, MIM:617747, NM_001308162, NM_001308163, NM_001352892, NM_001352893, NM_001352894, NM_138402, NP_001295091, NP_001295092, NP_001339821, NP_001339822, NP_001339823, NP_612411, NR_148198, SP140 nuclear body protein like, SP140L, XM_006712856, XM_011512190, XM_011512191, XM_017005294, XM_017005295, XM_017005296, XM_017005297, XM_017005298, XM_017005299, XM_017005301, XP_006712919, XP_011510492, XP_011510493, XP_016860783, XP_016860784, XP_016860785, XP_016860786, XP_016860787, XP_016860788, XP_016860790, XR_001739075, XR_002959365, XR_923066
Omim:OMIM:617747
Id:ENSG00000185404
Hgnc:HGNC:25105
Entrez:93349
Description:SP140 like nuclear body protein
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nuclear body. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SP140L's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SP140L.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SP140L.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SP140L.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SP140L.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.